8/18/2026
Genetix partners with the National Football League Alumni Association to raise awareness of sickle cell disease and help patients, families, and healthcare providers better understand available treatment options and support services.
6/23/2026
Through a strategic collaboration with SPIMACO, Genetix seeks to expand access to LYFGENIA™ and ZYNTEGLO™ while advancing localized manufacturing capabilities across Saudi Arabia and the broader Middle East.
3/2/2026
Following a year of significant revenue and patient growth, Genetix shares 2025 performance results and its 2026 strategy to expand capacity, broaden access, and drive continued commercial momentum.
12/8/2025
At the American Society of Hematology (ASH) Annual Meeting, Genetix shares new real-world commercial data demonstrating the value proposition of one-time, durable gene therapy.
12/6/2025
Selected for ASH’s exclusive press program, Genetix presents real-world data showing rising adoption and faster access for its one-time gene therapies.
11/3/2025
Genetix will be presenting real-world data on access, coverage, and the patient journey in sickle cell disease and transfusion-dependent beta-thalassemia at the 67th American Society of Hematology Annual Meeting.
9/18/2025
Read the full rebrand story of why we became Genetix Biotherapeutics, returning to our foundational roots and renewing our commitment to delivering transformative genetic therapies.
Continue Exploring
See how we evolved from innovation to real-world impact
Discover our FDA-approved treatments for rare genetic diseases